Psoriasis patients who had responded with a Psoriasis Area and Severity Index (PASI) score of a 75 or greater decrease from baseline at weeks 16 and 33 in a double-blind, randomized, placebo-controlled trial of adalimumab were re-randomized at weeks 33-52. They were re-randomized to either adalimumab (n = 250) or placebo (n = 240). Patients who completed this phase or lost adequate response could then receive an open-label extension (OLE) on adalimumab for 24 weeks. Post hoc analysis of the 227 patients who received placebo in the re-randomization phase determined their PASI responses at OLE week 24 (relative to baseline) for patients grouped by PASI response at week 0, in addition ...